Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Guelph

$27,000.00

The effects of a lytic peptide phor-21 conjugated to beta chorionic gonadotropin (ßCG) or GnRH on ovarian dynamics in ewes

FY 2010-11

Summary
Reproductive tissue cancers represent a major concern for Canadian men and women. Breast and prostate cancers fall behind only lung cancer as the leading number of new clinical cases. Millions of Canadian dollars and countless resources have been utilized in an attempt to increase the survival rates associated with reproductive cancers. Although the survival rates of the primary, localized disease have increased by almost 100%, the prognosis for patients with distant, metastatic disease is still very poor and this has not changed for more than thirty years. Conventional cancer therapy (i.e., radiation and chemotherapy) is associated with severe unwanted systemic effects and multi-drug resistance. This led to the development of new, targeted cancer treatments that show the ability to eliminate both primary and advanced, or metastatic, tumours. This therapy utilizes peptide hormones or their receptor-binding fragments as molecular cytotoxic transporters carrying lytic peptides to cells expressing compliment receptors. The conjugates currently under investigation utilize gonadotropin releasing hormone (GnRH) or luteinizing-hormone (LH) receptors. The distinct advantage of targeting these receptors is that they are densely expressed on reproductive tissue tumors but negligible in other organs. However, high-affinity GnRH receptors are also densely expressed in the anterior pituitary gland and LH receptors are abundant in ovaries around ovulation. To date, no studies have evaluated the effects of the conjugates on GnRH- and LH-mediated reproductive processes. As these drugs move towards human clinical trials, it will be of great value to have evidence indicating their impact on the dynamic ovarian function in a large animal model. Therefore, our primary goal is to assess the effects of the conjugated lytic peptides on the pituitary function and ovarian dynamics in ewes. The results of the studies determining the effects of these drugs on the reproductive organs may have important bearing on their use in a cancer therapy and, potentially, in contraceptive and luteolytic roles in future.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
311647-2010
Name nom
Bartlewski, Pawel
Department département
Biomedical Sciences
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
27000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5505
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Animal reproduction
Research subject fr
Reproduction animale
Partie
1
Nb partie
1
Application title
The effects of a lytic peptide phor-21 conjugated to beta chorionic gonadotropin (ßCG) or GnRH on ovarian dynamics in ewes
Keyword
NSERC
Application summary
Reproductive tissue cancers represent a major concern for Canadian men and women. Breast and prostate cancers fall behind only lung cancer as the leading number of new clinical cases. Millions of Canadian dollars and countless resources have been utilized in an attempt to increase the survival rates associated with reproductive cancers. Although the survival rates of the primary, localized disease have increased by almost 100%, the prognosis for patients with distant, metastatic disease is still very poor and this has not changed for more than thirty years. Conventional cancer therapy (i.e., radiation and chemotherapy) is associated with severe unwanted systemic effects and multi-drug resistance. This led to the development of new, targeted cancer treatments that show the ability to eliminate both primary and advanced, or metastatic, tumours. This therapy utilizes peptide hormones or their receptor-binding fragments as molecular cytotoxic transporters carrying lytic peptides to cells expressing compliment receptors. The conjugates currently under investigation utilize gonadotropin releasing hormone (GnRH) or luteinizing-hormone (LH) receptors. The distinct advantage of targeting these receptors is that they are densely expressed on reproductive tissue tumors but negligible in other organs. However, high-affinity GnRH receptors are also densely expressed in the anterior pituitary gland and LH receptors are abundant in ovaries around ovulation. To date, no studies have evaluated the effects of the conjugates on GnRH- and LH-mediated reproductive processes. As these drugs move towards human clinical trials, it will be of great value to have evidence indicating their impact on the dynamic ovarian function in a large animal model. Therefore, our primary goal is to assess the effects of the conjugated lytic peptides on the pituitary function and ovarian dynamics in ewes. The results of the studies determining the effects of these drugs on the reproductive organs may have important bearing on their use in a cancer therapy and, potentially, in contraceptive and luteolytic roles in future.